Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 12Recruiting 8Terminated 7Active not recruiting 7Withdrawn 3Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Neoplasms 1

Interventions

Nivolumab 23pembrolizumab 19Ipilimumab 13toripalimab 12Temozolomide 11Biopsy 8Dacarbazine 7Blood Specimen Collection 6trametinib 5dabrafenib 5camrelizumab 5atezolizumab 5Gene Expression Profiling 5Cyclophosphamide 5Chemotherapy, Adjuvant 5fludarabine 4durvalumab 4binimetinib 4aldesleukin 4Injections 4tislelizumab 3palbociclib 3encorafenib 3apatinib 3Sorafenib 3Introns 3Interleukin-2 3Drug Therapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Melanoma × encorafenib × Clear all
NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Leiden University Medical Center

Phase 2 Unknown
28 enrolled
Dermatologic

Melanoma

NCT05097378 2021-10-28

PREMIUM

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown
45 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡